MPR Weekly Dose

MPR Weekly Dose 132 — Social Media Warning; Cisplatin-Associated Ototoxicity Tx; New Cerebral Adrenoleukodystrophy Tx; MRI Contrast Agent; Generic Tazorac

Sep 23, 2022

This week we go over warnings about a new social media challenge; treatment approvals in cisplatin-associated ototoxicity, cerebral adrenoleukodystrophy, MRI contrast agents and a generic version of tazorac.

MPR Weekly Dose 131 — Approvals in Plaque Psoriasis, Hepatorenal Syndrome and Neutropenia; Priority Review for Rett Syndrome Therapy; Multivitamins Assessed in Cognition

Sep 16, 2022

Approvals in psoriasis, hepatorenal syndrome, and neutropenia; novel therapy gains Priority Review for Rett Syndrome; and the effects of multivitamin supplementation assessed on cognitive function.

MPR Weekly Dose 130 — FDA Vote on ALS Treatment; CPAP, BiPAP Recall; CRISPR Therapy for Hereditary Angioedema; Imfinzi Approved for Biliary Tract Cancer; Spevigo Approved

Sep 9, 2022

Hello listener and welcome to episode 130 of the MPR Weekly Dose Podcast. This week we have news of the FDA’s vote on an ALS treatment; CPAP and BiPAP device recalls; Orphan Drug designation for a novel CRISPR therapy; Imfinzi gains new approval; and Spevigo is approved for pustular psoriasis flares.

MPR Weekly Dose 129 — Omicron-Adapted Booster Dose; Influenza Season Guidance; Nirmatrelvir Efficacy; DEA Warn Over “Rainbow Fentanyl”; Chronic Idiopathic Constipation Tx

Sep 1, 2022

Omicron-adapted COVID-19 booster vaccines; guidance for the 2022-23 influenza season; efficacy of COVID-19 antiviral; ‘rainbow fentanly’ targeting youth; and a device to treat chronic idiopathic constipation.